Xi-shan Wu

发表

Structure-Based Discovery and Optimization of Furo[3,2-c]pyridin-4(5H)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors.

Yan Zhang, Yong Xu, H. Xu, 2022, Journal of medicinal chemistry.

Structural insights revealed by the cocrystal structure of CCS1477 in complex with CBP bromodomain.

Yan Zhang, Qiu-ping Xiang, Yong Xu, 2022, Biochemical and biophysical research communications.

Design, synthesis and pharmacological characterization of N-(3-ethylbenzo[d]isoxazol-5-yl) sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia

Yan Zhang, Xiao-yu Luo, Yong Xu, 2022, Acta Pharmacologica Sinica.

Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.

Yan Zhang, Donghai Wu, Benqiang Yao, 2022, Journal of medicinal chemistry.

Discovery and optimization of novel N-benzyl-3,6-dimethylbenzo[d]isoxazol-5-amine derivatives as potent and selective TRIM24 bromodomain inhibitors with potential anti-cancer activities.

Yan Zhang, Yong Xu, Donghai Wu, 2019, Bioorganic chemistry.

Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).

Yan Zhang, Yong Xu, Donghai Wu, 2018, Journal of medicinal chemistry.

Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.

Yan Zhang, Yong Xu, Donghai Wu, 2019, Journal of medicinal chemistry.

Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.

Yan Zhang, Yong Xu, X. Kong, 2021, Journal of medicinal chemistry.

Identification of N-phenyl-2-(N-phenylphenylsulfonamido)acetamides as new RORγ inverse agonists: Virtual screening, structure-based optimization, and biological evaluation.

Yu Song, Yan Zhang, Xishan Wu, 2016, European journal of medicinal chemistry.

Rational design, synthesis and biological evaluation of benzo[d]isoxazole derivatives as potent BET bivalent inhibitors for potential treatment of prostate cancer.

Yan Zhang, Yong Xu, Qiu-ping Xiang, 2023, Bioorganic chemistry.

Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse Agonist.

Yan Zhang, Yong Xu, Donghai Wu, 2021, Journal of Medicinal Chemistry.

Discovery and structural optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-ones as RORc inverse agonists

Yan Zhang, Xiao-yu Luo, Yong Xu, 2016, Acta Pharmacologica Sinica.

Discovery of a potent and selective CBP bromodomain inhibitor (Y08262) for treating acute myeloid leukemia

Yan Zhang, Qiu-ping Xiang, Tian Wu, 2023, Bioorganic Chemistry.

Liver receptor homolog-1: structures, related diseases, and drug discovery.

Xi-shan Wu, Yong Xu, Tong Wu, 2024, Acta pharmacologica Sinica.

Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity.

Yan Zhang, Tian Wu, Xiaoshan Chen, 2024, Journal of medicinal chemistry.